SciELO - Scientific Electronic Library Online

 
vol.64 issue5Follicular Lesions with Papillary Nuclear Characteristics: Differences in Chromatin Detected by Computerized Image Analysis author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Archives of Endocrinology and Metabolism

Print version ISSN 2359-3997On-line version ISSN 2359-4292

Arch. Endocrinol. Metab. vol.64 no.5 São Paulo Sept./Oct. 2020  Epub Oct 16, 2020

https://doi.org/10.20945/2359-3997000000305 

This corrects the article: 10.20945/2359-3997000000258

Erratum

Reference values of 25-hydroxyvitamin D revisited: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC)


DOI: 10.20945/2359-3997000000258

Arch Endocrinol Metab. 2020;64(4):462-78

Where you read (TITLE):

Reference values of 25-hydroxyvitamin D revisited: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC)

Should read:

Reference values of 25-hydroxyvitamin D revisited: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine ( SBPC/ML )

Where you read (TEXT):

These assays include a first step in which 25(OH)D is dissociated from its carrier proteins. In a second step, the 25(OH)D in the sample competes with an analogue for the same sites of the ligand's assay [anti-25(OH)D or DBP antibodies] .

Should read:

These assays include a first step in which 25(OH)D is dissociated from its carrier proteins. In a second step, the 25(OH)D in the sample competes with an analogue for the same sites of the ligand's assay [anti-25(OH)D antibodies and DBP] .

Where you read:

Table 2 Clinical conditions and groups that benefit from 25-hydroxyvitamin (25[OH]D) concentrations above 30 ng/mL 

Groups Clinical Conditions
Elderly (> 65 years) Osteoporosis (primary or secondary)
Pregnant women Fractures due to fragility
Metabolic bone diseases (osteomalacia, osteogenesis imperfecta, primary hyperparathyroidism)
Secondary hyperparathyroidism
Sarcopenia
Recurring falls
Chronic renal disease
Malabsorption syndrome
Liver failure
Anorexia nervosa
Cancer

Should read:

Table 2 Clinical conditions and groups that benefit from 25-hydroxyvitamin (25[OH]D) concentrations above 30 ng/mL 

Groups Clinical Conditions
Elderly (> 65 years) Osteoporosis (primary or secondary)
Pregnant women Fractures due to fragility
Metabolic bone diseases (osteomalacia, osteogenesis imperfecta, primary hyperparathyroidism)
Secondary hyperparathyroidism
Sarcopenia
Recurring falls
Chronic renal disease
Malabsorption syndrome
Liver failure
Diabetes mellitus type 1
Cancer

Where you read:

Correspondence to:

Carolina Moreira

Rua Leão Júnior, 285

80060-000 – Curitiba, PR Brasil

carolina.aguiar.moreira@gmail.com

Should read:

Carolina Moreira

Av Agostinho Leão Júnior, 285

80060-000 – Curitiba, PR Brasil

carolina.aguiar.moreira@gmail.com

Creative Commons License This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.